Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect and Safety of PCSK9 Inhibitors on the Progression of Mild/Middle Calcific Aortic Stenosis: A Randomized Controlled Clinical Trial

NCT07256197 is registered in ClinicalTrials.gov with Beijing Anzhen Hospital as lead sponsor.

NCT NCT07256197
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07256197 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect and Safety of PCSK9 Inhibitors on the Progression of Mild/Middle Calcific Aortic Stenosis: A Randomized Controlled Clinical Trial
Lead sponsor
Beijing Anzhen Hospital
Phase
Phase 3
Overall status
Not yet recruiting
Start date
April 1, 2026
Completion date
January 31, 2029
Enrollment
160 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aortic stenosis, calcific